European Journal of Cardiovascular Medicine

Numerous medications are now approved to treat and relieve symptoms related to Alzheimer's Disease (A.D.). Most of these drugs regulate the neurotransmitters, thereby modulating the transmission of messages between neurons. However, these drugs are helpful in the reduction of A.D. symptoms associated with particular behavioral problems but are unable to change the underlying pathophysiological process accounting for the disease. In addition, their effectiveness is limited for a small group of people and thus may be helpful for a limited period. Therefore, the scientists are investigating the possible strategies for the symptomatic treatment and finding out the ways to hold back or prevent the disease. Drug development and assessment for newer and better drugs as well as treatment methodologies are caring out by the scientists in ongoing clinical trials. This study has been carried out to accumulate the different treatment strategies, including drug therapies intended for various targets such as loss of specific neurotransmitters & synapses, cerebrovascular function, neurofibrillary tangles & beta-amyloid plaques, as well as other nondrug approaches